Continue Reading To Discover The Specific Receptor That May Be Causing Bodyfat To "Automatically" Stick To Your Abs Like Crazy - Refusing To Let Go...
 Super Thermogenic
Introducing a burner coined the "Super Thermogenic™" by those familiar with its effectiveness...
It's called OxyELITE Pro™ & It’s absolutely unmatched!
Why Is The Last Place To Lose Fat, The First Place To Gain Fat?
It just doesn't seem fair...
...It may be your stomach, your love handles or another unsightly part of your body...
Fat can stick to these areas like super glue and hang on for dear life...
So why does this happen?
Your BodyFat Held Hostage?
It's called the Alpha-2 receptor – And, if getting ripped is your goal – it can be your absolute worst enemy...
If the Alpha-2 receptor wants you to store fat, you're going to store fat ...
The alpha-2 receptor is responsible for inhibiting lipolysis - which basically means it can allow the body to store fat AND prevent the body from burning it...
In other words, the Alpha-2 receptor can hold your fat hostage & refuse to let go!
The Alpha-2 Receptor is abundant in certain areas of your body & virtually non-existent in others...
As you can see in the illustration above, Alpha-2 receptors have been shown to be present in abdominals, love handles, and buttocks – precisely where you don't want them to be!
This is exactly why your biceps can get lean, yet your stomach’s as smooth as a baby's ass...
The Alpha-2 Receptor is the technical term for "trouble spots"...
When it's activated, these areas can go into "lock-down" - storing fat like a bear preparing for hibernation... Is Your Fat Burner Targeting The Wrong Fat?
Notice that we said subcutaneous fat cells as this is where many companies fail to make a distinction when creating thermogenics...
Many compounds can produce a decrease in fat mass when it comes to visceral fat (i.e., the fat that surrounds your organs), but when it comes to improving how you look, subcutaneous fat is what you're concerned with as this is the fat that is just below your skin and smothers up your muscles... How Much Subcutaneous Fat You Have Means The Difference Between Looking Shredded Or Looking Like You Own Stock In A Donut House.
As you can see in the picture above, subcutaneous fat is what covers up your abs. Most crappy high-stim thermogenics these days target visceral fat, not subcutaneous fat.
As you can see above, targeting visceral fat alone isn't going to do much for that layer of fat surrounding your muscles...
You need to get rid of excess subcutaneous fat to make a lean physique a reality.
Buy USPlabs OxyELITE Pro™ NOW!
Best,
P.S. To truly maximize the result of any supplement, you must combine with proper nutrition & exercise plans. Feel free to visit our forums for information.
P.P.S. It's mandatory that athletes or anyone subject to testing check with their governing body before using this product. Read the entire label, including directions, precautions & warnings. Tested athletes make up the extreme minority of the American public and have to follow strict rules on what they can and cannot use in competition. For example, compounds such as caffeine, creatine & 1,3 dimethylamylamine (also known as methylhexanamine, 2-amino-4-methylhexane & 1,3-dimethylpentylamine) may not be allowed by your specific sports organization. It’s completely up to the user to get this and any dietary supplement cleared by their organization before using.
Directions for use: As a dietary supplement, begin by taking 1 capsule on an empty stomach
before breakfast for the first three (3) days. An additional 1 capsule six to eight hours later on an empty stomach may be taken starting on day 4. Once the above steps have been taken, an additional capsule may be added to the morning dose. The majority of users will not need to increase dose. Under no circumstances should the initial dose be exceeded or the warnings on this bottle be ignored.
DO NOT USE PRODUCT FOR LONGER THAN 8 WEEKS FOLLOWED BY A SUBSEQUENT 4 WEEK BREAK. DO NOT EXCEED 3 CAPSULES IN ANY 24 HOUR PERIOD. Exceeding the recommended amounts or not following directions may lead to unwanted effects. Consume at least 125 Fl. Oz. of liquid per day for men and 91 Fl. Oz. of liquid per day for women while taking this product. Store in cool dry place. Discard after expiration date.
Warning: This product is only intended to be consumed by healthy adults 18 years of age or older. Pregnant or nursing women should not use this product. Consult with your health care
provider before using this product, especially if you are taking any prescription, over the counter
medication, dietary supplement product or if you have any pre-existing medical condition
including but not limited to: high or low blood pressure, cardiac arrhythmia, stroke, heart, liver,
kidney or thyroid disease, seizure disorder, psychiatric disease, diabetes, difficulty urinating
due to prostate enlargement or if you are taking a MAO-B inhibitor or any other medication,
including but not limited to MAOIs, SSRIs or any other compounds with serotonergic activity
This product contains caffeine and should not be taken by individuals wishing to eliminate this
ingredient from their diet. Discontinue use 2 weeks prior to surgery. Do not use in combination
with caffeine or any stimulants from other sources whatsoever, including but not limited to,
coffee, tea, soda and other dietary supplements or medications. Do not combine with alcohol.
Discontinue use and immediately consult your health care professional if you experience any
adverse reaction to this product. Do not exceed recommended serving. Do not use if safety seal
is broken or missing. KEEP OUT OF REACH OF CHILDREN.
Other Ingredients: Modified Starch, Gelatin, Vegetable Stearate, Silicon
Dioxide, Red 3, Blue 1, Red 40, Titanium Dioxide Color. |
References
- Anonymous. New and nonofficial remedies: methylhexamine; forthane. J Am Med Assoc. 1950 Jul 29;143(13):1156
- Swanson EE and Chen KK. Comparison of pressor action of aliphatic amines. J Pharmacol Exp Ther. 1946 88(1):10-13
- Charlier R. Pharmacology of 2-amino-4-methylhexane. Private Trans. Arch Int Pharmacodyn Ther. 1950 Sep 1;83(4):573-584
- Diepvens K, Westerterp KR, Westerterp-Plantenga MS. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R77-85
- Mori S, Satou M, Kanazawa S, et al. Body fat mass reduction and up-regulation of uncoupling protein by novel lipolysis-promoting plant extract. Int J Biol Sci 2009;5(4):311-318
- Bracco D, Ferrarra JM, Arnaud MJ, et al. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol. 1995 Oct;269(4 Pt 1):E671-E678
- Dullo AG, Geissler CA, Horton T, et al. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr. 1989 Jan;49(1):44-50
- Acheson KJ, Gremaud G, Meirim I, et al. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr. 2004 Jan;79(1):40-46
- Kaplan GB, Greenblatt DJ, Ehrenberg BL, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997 Aug;37(8):693-703
- Smith A. Effects of caffeine on human behavior. Food Chem Toxicol. 2002 Sep;40(9):1243-1255
- Berlan M, Galitzky J, Riviere D, et al. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes. 1991 May;15(5):305-315
- Galitzky J, Taouis M, Berlan M, et al. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. 1988 Dec;18(6):587-594
- Flechtner-Mors M, Jenkinson CP, Alt A, et al. In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects. J Pharmacol Exp Ther. 2002 Apr;301(1):229-233
- Sax L. Yohimbine does not affect fat distribution in men. Int J Obes. 1991 Sep;15(9):561-565
- Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming drug? Isr J Med Sci. 1991 Oct;27(10):550-556
- Berlin I, Stalla-Bourdillon A, Thuillier Y, et al. Lack of efficacy of yohimbine in the treatment of obesity. J Pharmacol. 1986 Jul-Sep;17(3):343-347
- Zahorska-Markiewicz B, Kucio C, et al. Adrenergic control of lipolysis and metabolic responses in obesity. Horm Metab Res. 1986 Oct;18(10):693-697
- Perry BD, U'Prichard DC. [3H]rauwolscine (alpha-yohimbine): a specific antagonist radioligand for brain alpha 2-adrenergic receptors. Eur J Pharmacol. 1981 Dec 17;76(4):461-464
- Berlan M, Le Verge R, Galitzky J, et al. Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine. Br J Pharmacol. 1993 Apr;108(4):927-932
- Kronenberg HM, Melmed S, Polonsky KS, Larsen PR.: Williams Textbook of Endocrinology, 11th ed., Saunders Elsevier, Philadelpha, PA, 2008.
- Panda S, Kar A. Withania somnifera and Bauhinia purpurea in the regulation of circulating thyroid hormone concentrations in female mice. J Ethnopharmacol. 1999 Nov 1;67(2):233-239
- Jatwa R, Kar A. Amelioration of metformin-induced hypothyroidism by Withania somnifera and Bauhinia purpurea extracts in Type 2 diabetic mice. Phytother Res. 2009 Aug;23(8):1140-1145
- Kar A, Panda S, Bharti S. Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice. J Ethnopharmacol. 2002 Jul;81(2):281-285
- van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009 Apr 9;360(15):1500-1508
- Fruhbeck G, Becerril S, Sainz N, et al. BAT: a new target for human obesity? Trends Pharmacol Sci 2009 Aug;30(8):387-396
- Cypress AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009 Apr 9;360(15):1509-1517
- Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009 Apr 9;360(15):1518-1525
- Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004 Jan;84(1):277-359
- Celi FS. Brown adipose tissue—when it pays to be inefficient. N Engl J Med. 2009 Apr 9;360(15):1553-1556
- Robertson D, Frolich JC, Carr RK, et al. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med. 1978 Jan 26;298(4):181-186
- Silva JE, Larsen PR. Adrenergic activation of triiodothyronine production in brown adipose tissue. Nature. 1983 Oct 20-26;305(5936):712-713
- Raasmaja A, York DA. Pharmacological characterization of alpha1- and beta-adrenergic synergism of 5'DII activity in rat brown adipocytes. Arch Physiol Biochem. 2006 Feb;112(1):23-30
- Hellstrom L, Wahrenberg H, Reynisdottir S, et al. Catecholamine-induced adipocyte lipolysis in human hyperthyroidism. J Clin Endocrinol Metab. 1997 Jan;82(1):159-166
- Neylon CB, Summers RJ. [3H]-rauwolscine binding to alpha 2-adrenoceptors in the mammalian kidney: apparent receptor heterogeneity between species. Br J Pharmacol. 1985 June;85(2):349-359
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Individual results may vary. |
